Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Cannabis-Derived drug help COPD patients breathe easier?

NCT ID NCT06473701

Symptom relief Sponsor: Vejle Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study tests whether dronabinol, a synthetic form of THC (the psychoactive compound in cannabis), can reduce severe breathlessness in people with advanced COPD. Thirty participants will receive both dronabinol and a placebo in random order to compare effects. The goal is to see if the drug improves daily comfort and activity levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dronabinol (synthetic THC)
What this could lead to
If it works, this could offer a new option to ease severe breathlessness in advanced COPD patients who have few other treatments.
What could go wrong
This is a small early-phase trial with only 30 people, so results may not apply widely. Dronabinol can cause side effects like dizziness or confusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Refractory dyspnea despite optimal treatment * COPD (GOLD 3,4) * Breathlessness corresponding to mMRC score ≥ 3 * Informed written consent * Age ≥ 18 years * Cognitive relevant, of legal age * Understands and speaks Danish * For fertile women defined by amenorrhea for less than 12 months: negative HCG before entry into the trial * For fertile and sexually active subjects: use of safe contraception during medication intake and 4 weeks after: intrauterine device (IUD) or hormonal contraception (oral contraceptive pill, implant, transdermal patch, vaginal ring or depot injection). Exclusion Criteria: * Ongoing infection or exacerbation of COPD within the last month (30 days) * Regular treatment with THC or CBD within 1 month (30 days) * Life expectancy less than 3 months (90 days) * Treatment with medicines that, according to the summary of product characteristics, are strong inhibitors or inducers of CYP3A4, CYP2C9 or CYP2C19 * History of or current evidence of significant medical or psychiatric disorder that is considered by the investigator to put the subject at greater risk of experiencing an adverse event * Current or past substance abuse where the investigator finds it too risky for the subject to be included in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breathlessness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence chronic obstructive pulmonary disease COPD, severe early onset Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breathlessness Cannabis COPD

Contacts and locations

Locations

  • Vejle Hospital - A part of Lillebaelt Hospital

    Vejle, Region Syddanmark, 7100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.